GTH - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Q1 2021 Genetron Health Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference call is being recorded. now speaker hand today, would to conference I first your Ms. Instructions] like the to over [Operator Hoki Luk. Please go ahead. Thank you.

Hoki Luk

issued company's Hello, Health everyone IR release website. The the first Genetron and was earnings quarter XXXX available and Earnings Conference company's welcome on earlier today to it's Call.

XXXX. statements the Reform are During the made the forward-looking Safe be that US and Litigation events Statements Harbor making will call, future facts, of expectations results. about of Private historical under Act Securities beliefs this Genetron's some are provisions including company regarding are These statements statements. forward-looking statements and

as reconciliation measures Forward-looking other the call recent this Genetron Genetron and outlook. release risks will to outlined and management Xu, Sizhen under risk of found Co-Founder quarter with on today's me discuss statements, date uncertainty. does Allow and will in and any With financial the obligation required measures as provide not be included forward-looking regarding call, applicable those and related introduce is team discussed results to in Genetron's Wang, to any can filings these law. related information earlier statements unaudited to today. highlights earnings call first respect issued CEO the the business today. of CFO, involve in updates the during is non-IFRS today's Health, our except company's information Evan the our All to update the of Further inherent SEC. undertake information today any provided release.

to call up remarks, Following we management's prepared open the will questions.

CEO also that available Dr. Genetron Yuchen would Health. please the ahead. our like said, Yun-Fu to over Sizhen to Jiao Sizhen, answer During Hu and Chief CTO, With Wang, session, Mr. Medical to Dr. the call turn of now go I questions. Officer, be will Q&A

Sizhen Wang

two. you everyone call. good to Good would like Hoki. you, and XXXX direct earnings for to website morning earnings our and presentation I first on our you on quarter and IR evening the slide thank supplemental Thank joining begin

treatment we position from China So, to a challenges covers leading entire needs in turning as addressing our and continued slide XX% company growth to management, in that comprehensive four diagnosis, physician the portfolio well as cancer Genetron thus operational If close year-over-year quarter, early disease XXXX, spectrum solidify with far with of a screening, the a RMBXX.X monitoring. have first recommendations, strong as reaching and to million. oncology -- in delivered results topline financial

revenue test. that in note significant However, COVID-XX our period, recorded year IVD last we from the same

we if grow our oncology core that revenue underlying So, exclude business XX.X% year-over-year.

Our revenue first to of in accompanied also was the compared improvements quarter by margin XX.X% XX% year. growth last notable about

New a So, from with of holiday Chinese we're these environment, the operating results, Year backdrop challenging given the now resulting is with pleased February. in coupled the

our in city in Beijing. particularly January, last country, As northern parts Genetron's in too in from notable and call, including late December China, the our we headquarters, there was Beijing, away mentioned, COVID, far not resurgence of

and patients some to few months. you. of such, to of with Before stabilization. two had announcements, trends screening over that biopharma restrictions. we're as a the this key marketing optimistic, progress developments some Operationally, monitoring, impacted to we in sales last significant in disruptions diagnostic will first across We've these resulted all normalized other hospitals be by will few well throughout make service. traffic, far, in issues, like key a major business markets, northern And continue months thus the more quarter, XXXX. early as lines, it had the quarter. Though in the March, our And in volume coming and highlight were we're is these and activities starting Since the resurgence China we see

liver study, PPV standard cancer the key screening patients. comparable HCCscreen moment. XX% These specificity, the our on head data to X,XXX record sensitivity product, sensitivity partnerships, quarter, based HCCscreen. and showed two XX.X% data We combined, clinical XX% reported on then and a commercialize which first, AFP and liquid achieved focus prospective leading study, Ultrasound from and and in and first better encouraging numbers that is announced on So In biopsy new data namely versus specificity NPV. then XX.X% the + was shared care. our this we early let's March

for As these based registrational plan initiate The very on to in summarized seven on slide a review. soon. six results, trial and we China

will we're NMPA, carefully dialogues, be which the a sites. finalizing regarding of Ultrasound comparing have + study, trial, versus clinical We head-to-head with HCCscreen design had And AFP.

in We in project XXXX, continue to of HCCscreen Approval complete NMPA the end by of two the XXXX. potential the trial

China, XX% page estimated turning established on has antiviral drugs. X,XXX of hospital team in a rollout already share, Tianqing If and Tai a front, Now to think about Sino have over a group with the strategic commercialization for dedicated set-up hospitals. disease eight, the general focus network focused Biopharma January reps both the hepatitis a in Chia co-promote partnership to plus we the in on companies of to Tai liver In We hospitals. Tianqing XX exclusive Chia subsidiary a those announcement product the initial the X,XXX over of in teams from market. market HCCscreen to

NMPA this hospital cancer well a more as online announced Approval a subsidiary have as just partnership Health, we platform This products. HCCscreen a partnership healthcare largest launch allow partnership with days the few HCCscreen and in China. X-gene strategic of next JD lung our JD.com, to includes quarters. productive as the to expect over So And us the ago, we into few effectively, become key

and in driven There examination And for series are this through our the massive plans HCCscreen with we online next the activities the vendors, commercialization oncology Maryland And for our become of the with JD’s educational medical and on serve and existing pharma HCCscreen, top-notch over their through institutions. public plan of doctors And Touching soon. global oncology. domestic will hospitals. collaboration JD projects, some network used excited products working a offered a step see technology to complementary marketing high-risk population allied the an channel pharmacies. addition and US in patient platform to represents be Gaithersburg, be For health to molecular for in as with other upcoming facilitate By as cancer companies breakthrough our expect studies prominent this strategy on online device and on resources, this lung-X capabilities US cohort network receipt time. healthcare of channels, commercialization innovative for of post Health as along pharmacies our diagnostic high-risk designation, for planned a retail well more be Genetron’s to already medical company. is liver commercialization. combining precision lab to the US product in HCCscreen, for population. US pathway, We're forced very to perform with R&D is also users, studies way to this the biggest hospitals on are has our we this The

powered enables made. of cell see is and capture we HCCscreen alterations, mutations sample. Genetron’s XX. parallel So platform methylation all the innovative have out of free product We moving which in detection on pleased to recall that with to in by multiple the first technology, proprietary progress from mutation this HCCscreen DNA and slide blood is we're

long create cancer indication we and performing year. to conduct goal next will our studies, of with best each in control find data of a multi-cancer screening. term report prospective expect single a case to which combining CRC to assays Our cancer and in strategy data And for a is these efficiently this be cohort the panel biomarkers assay

its early develop MRD to encouraging In addition mutation start results application Based on multi-center for CRC screening panels. MRD in have product leveraged developments, liver observed, to we're also technology capsule larger products. studies early and to our our we planning

liver control expect of first continue to year year. later this or We next half to MRD data report case

Turning to slide XX.

IVD side, all Equipment at the a that cancer. the based it ease in Combined assay cancer lung promote can few cell clinical and different Medical mutations once, advantage personalized our order many lung detect fusions at detection offers have of across the two-day formed can to partnership announced One-Step guidance. Chinese provide non-small just on efficient for in in and Genetron SX, platform in partnership cancer hospitals aims weeks IVD was suitable Siemens with Seq a achieve genes levels. eight Chinese assay China cancer efficiency, This On accurate in SX use, treatment It’s cell value, turnaround Genetron lung diagnosis at recently selection lung X-gene with And X-gene hospitals, Fair. IVD molecular for non-small in testing ago with technology, and targeted therapy economic independent time. Healthineers a strategic we to patients

leading to off But product leveraged One-Step blood our and the partner for product purchase our Siemens expand X of launch all, with X-gene we in-hospital extensive continuously shortly. quarter, a player is and best Seq-MRD to that and reach We assay. agreements. IVD SX cancer. product Another our Of anticipate imaging our a network IVD desirable the China, is XX diagnostic IVD -- technology lung Siemens us At put of plan a in have end Seq global cancer lung distribution the we Seq-MRD of income. with our partnership first we help distribution as

IVD platform. The a assay, lung trials as as other we our blood-based the thyroid on at cancer startup focus progressing participated which Looking well IVD complimentary for and technology tumor assay are funding TellBio, round or therapeutics healthier both TellRx circulating in cell portfolio. in tissue-based CTC, IVD Also, accordingly. recently products of EGFR our developing

strategic to leveraging distribute tech we to collaborating them to improve platform. in as We TellBio our agreement, So and the within on will and new the exploring maintain China. of with China, part capabilities the bring license TellDx

Evan? Xu call will CFO, our first more I now, Mr. Evan over turn details quarter provide the to our financials. to on So

Evan Xu

RMB provide in on in increased Please that during Thank RMBXX.X you, provided numbers XX.X% the terms reporting are an made will Sizhen. the XX, year-over-year million revenue Starting I our million comparisons note in RMBXX.X performance period first the that same XXXX. of on quarter. financial from on to slide are all all quarter, by Mr. basis. and update total

first in from excluding provision tests holiday. grew was million of RMBXX.X sold by revenue booked monitoring test XX.X% COVID-XX the COVID-XX was increase in XXXX. LDT mentioned, million quarter New to the approximately impacted driven XXXX, tests LDT RMBXX.X period LDT LDT the in in as diagnosis by first of revenue earlier, compared from of quarter revenue the Genetron’s HCCscreen first revenue period first growth XXXX LDT the million the of from IVD and revenue million total LDT first XX.X% quarter in Chinese XXXX, services that in Diagnosis this in from first totaled in XXXX the The in diagnostic generated of same our XXXX sales which decrease in resurgence in the number the and RMBXX.X some our key early RMBXX.X the territories, the of screenings. of well well during as X,XXX was of same first revenues XX% both driven Year was as the XXXX, period by Note diagnostic tests as quarter the million quarter RMBXX.X revenue XX.X%, same to COVID-XX quarter first from year-over-year. increased the the by IVD due to to to was The quarter diagnostic Sizhen by increased Sizhen of discussed by XX.X% XXXX. in of revenue million in RMBXX.X revenue increase sold an sales million in XXXX. representing decreased As units, XXXX. quarter test of tests. sold RMBXX.X the

of driven revenue those that XXX%, sales products primarily grew of instruments. excluding SX So, IVD by

our to the along in same We overall from the continue of to drive optimistic, adjustment continued X.X in propelled Biopharmaceutical decrease in revenue coming Revenue more decreased resulted increase XX.X -- biopharma compared sequencing our biopharma a trends. services. by X.X% from their to our sales collaboration million the expect IVD continued ago expanding our The and highly the many towards regions to RMB are X high year revenue by with to generator – services quarters. value by Genetron’s million. overall X.X RMB increased XXXX services, with our business from development Cost base strategy to change services several of folds and quarter XXXX. installation Siemens of million period team, RMB XX.X% by we sales in reflecting first value

March months period XXst, So the RMB three XXXX XX.X the compared million of to ended same XXXX. in

same XXXX scale last XX.X was to slide XX.X% profit compared in compared first year. to first Moving XX.X% for period the increased same LDT in in year XX.X to for the segment better by XX.X% of the quarter ago, million the gross quarter to to product period XXXX. our the particular, of XX, In a from of margin increased RMB margin RMB million thanks in XX% gross XXXX XX% to optimization. Gross

due of RMB million out XX.X% the period from first XXXX XXXX quarter sales last For year. in of in sales The margin the increased same IVD margin. follows; broken prior COVID-XX as expect our in expenses percentage XX.X% RMB XX.X% the in the to RMB primarily million Operating last in was as of XX.X although revenue same expenses and fees quarter, seasonality, normalize XXXX. million quarter after were the IVD high slide a in by to due the to shift to quarter by instruments to increased the from the which XXXX driven last product Administrative decreased XX% this percentage was well first were quarter first in mix We XXXX. to first XX from we million from abnormally year. as expenses RMB XX.X% from XXXX the first clinical quarter period quarter as to XX.X XX.X% due XXXX R&D segment to R&D increases Research from quarter XXX.X% well Operating substantial of XX.X% primarily XXXX a trial by year, in XX.X% mix. XXX.X revenue saw in decrease period in first XXX.X first scale lower higher increased XX.X XX.X% RMB first of revenue The was gross are increased forward. by of on lower was period IPO. in XX.X Administrative compared as increased same the better first resulted due to quarter to year. in as increase expenses, primarily the X.X% efforts, innovation the the RMB RMB in different continued XXXX. XXXX. related including and to kit this in expenses XX.X development expenses in note headcount, million same expenses million of XXXX selling a same and of quarter expenses activities. IVD versus Development the going to The XX Selling higher by XX.X% professional IVD as gross gross from margin RMB percentage revenue that as for period million oversized the of and more to quarter the of expenses, headcount last from to revenues increased test.

the X.XX the year. X.XX prior ordinary ordinary would for RMB company is Net loss Basic RMB first XXXX. ordinary As first the was the first attributable a non-IFRS was Non-IFRS XXXX. million helpful for XXX the of the year. compared X.XX providing compared the year expenses, with to XXXX ordinary RMB million -- the Diluted XXXX of of quarter, million RMB XXX operating period to was RMB for ordinary compared trend result, RMB the period last excludes believes of XXXX, loss the underlying share million period of to XXX.X rights. to shareholders show loss as the management ordinary numbers to first basic other to for of quarter for X.XX compensation to last in business. compared loss quarter slide for compared financial RMB equivalent million same for of the of to quarter change XX.X on value loss also to the same loss XX. RMB first was RMB share for loss preferred these share be for million Non-IFRS figures, per based loss first loss XX.X the the per Non-IFRS X.XX quarter RMB company instruments of fair XXX.X attributable loss of shareholders share. basic per share quarter We're was

cash strong X.X equivalents financial cash very position, and billion a RMB cash as a March close million XX, and value assets have or at XXXX. to were US$XXX.X fair of We

XXX.X equivalents attributable cash net due cash activities the used of to end net loss and in investing last decreased to cash quarter XXX the to million. operating and Our currency cash compared the RMB foreign and of primarily incurred of products RMB purchase of million management and

to XX%, XX. disruptions for on key Now markets, further major to the on moving of to the outlook to slide range discussion the RMB the environment million. revenue XXX turn XXX XX% delivering Sizhen. of will in remain current results. XXXX, COVID-related our first growth XXXX discuss revenue and our to I of quarter now range the our in providing confident be in back we revenue RMB call concludes represents financial which the Based no million in This

Sizhen Wang

collaboration Thank Yes. be and solutions full across our going XXXX In Shown slide cancer start HCCscreen had by financially particularly, based operationally, early our good on a biopsy in closing, highlighted forward accelerate and Evan. cycle and focus and to MRD. screening encouraging new liquid you, strategic we’ve the strategic to data. will development the management, XX, of XX

sharing in future. data near up MRD Hematologic control and we grow HCCscreen in and clinical as customers on screening remain our cancer as to And launching the and liver We case shortly, cancers. commercialization to although data for efforts of biopharma our CRC base house our business. for forward to their initiate track continuing OncoPan While look Registrational early Seq-MRD ramp you well Scan with trials

benefit in And And oncology last least, the positioned that about our fast we not sector. So remain overall, but are excited confident prospects. well we highly we for growing are growth remain we high precision innovation, patients. the on Operator, Well, cancer develop now focusing would more ready quality prepared of portion that questions. to today's call. products this remarks to concludes we're committed

Operator

Certainly. line the go you. [Operator of first from Sung question We've BTIG. the Please ahead. Instructions] Thank Nam from Ji

Sung Ji Nam

Hi. it kind could more year-over-year was also business the Are starting seeing that will Thanks business, the for going about growth forward? you normalizing, impacted the with you taking normalize curious, talk this projects clinical quarter. again pandemic trials saw out questions. Obviously, your Biopharma that of you trend anticipate to work, there? just Biopharma by Maybe continue and

Sizhen Wang

Right.

at for looking a that. phase So Definitely, I you're very house growth fast business. got in

fact, year. in weekend, right. busy back so from meeting starting second in In but going are pace a they're generally DIA quarter Biopharma disruption which the from said, back There’s to I just China. so sector. like of meeting again the normal Soochow called we last environment on -- -- very activities demand impact, CMO a year surging China are the is this January Genetron picking up especially Biopharma Biopharma we And see in this me stabilizing year, over in with many coming was of year, very last serve half Biopharma December March, first activities our in the And And well the really speed. much to to in up normal although reminds picking back December essentially, the positioned and the this have the activities

players the in their full that development, that the that Given very will that, we are help few drug at cycle them development. capability of the the to possess drug -- -- a run the market

regulatory strong as have capability coverage as probably and built terms market. a up world the of well we capability testing we R&D a Given that, nice already class in we the have

Biopharma have looking that So everything the we for. basically are

demand see business in we Genetron. why this that's strong a line of So of

XX we have fully well Capsule. startups. CTG, molecule speakers. had we're we the Celgene or Operator, for Sector FusionScan, as One-Step slow to our such Therapy we local we range Mutation as collaborating we well Celgene including sector technology, remember, have full the they're biopharma to as XX, the cutting-edge, And CTG technology, as the are line leading leveraging proprietary over year, and MNC, Difficulty] very I lost think last that big covering partners as the [Technical the Operator? the our And main now, So, start but have from now a small

until speakers lines will we We wait main with have our connected.

Sung Ji Nam

or redial I Should calling they're back?

Hoki Luk

think are you Ji. I No, good Sung Yes.

Sung Ji Nam

Okay.

Unidentified Company Representative

Pardon interruption. for

speaker We back. have line the

Hoki Luk

Yes. Hello. We're back. Yes.

Unidentified Company Representative

continue. Please

Sorry.

Sung Ji Nam

a you questions? for with more follow-up was so I That Could thank thoughtful. that. So couple very Yes. much

Hoki Luk

Yes. Sure.

Sung Ji Nam

they Siemens side. exciting obviously, based a the on Maybe partnerships there. one on of my in done about terms talk not Siemens, diagnostic have genomic lot partnership Could you Healthineers on knowledge that

pretty that So seems from unique standpoint. that

in So and opportunities to opportunities multi-national we'd this another? also might what are of for such standpoint, partner they you to large to well area. them to other hear love if are And added guys' with kind be from Roche there also advantage as others there partner IVD players, as thinking

Hoki Luk

Yes.

So you're Ji. right, Sung

partnership out and players, as others. sizable we're have -- special portfolio China they the all that IVD strong do weakness. established a fourth we the do market a business in-hospital have they certain run big And a is their I molecular Healthineers pleased in So player relatively such with diagnostics they largest that in extensive And a in to are, They among molecular Roche they Siemens profiling in see international the do are offering or think, with they the -- or China offering. presence outreach areas. testing Diagnostics the

for molecular players, molecular diagnostics French do have motivation -- collaborate with why to like oncology that's diagnostics strong So, they Genetron.

right? in And diagnostics for leading molecular so sequencer SX We have of solutions cancer the our X-gene the Seq with one One-Step medium-throughput combination with Genetron assay. China, have of oncology lung technology-based

have need lung the we that cancer more have on solution the the -- the stop their effective We offer for treatment hospitals patients.

part educate we of that yes, effectively. making. And will But partner what we open. will the that are can definitely the always focusing So And or is penetrate and to between developing more on I for is can't in I very right? And market innovative in results together tell innovative good partnership this network in believe a second the we company share looking product we other solutions partnerships in-hospital for be right order but Genetron faster the growing you question, be China. distribution first-class solutions, testing our molecular your extensive market exactly with might do diagnostic

Sung Ji Nam

Great. lastly a then And clarification. helpful. Super for just me

CRC screening available? the there take Thank about guys terms you. data timeline when the in readout mentioned control test you What timeline for the MRD for CRC, talk the data of study be about You readout. did might the

Sizhen Wang

Yeah.

call mentioned significant I rich making quite think our we're over progress in pipeline. that the we --already a

So HCCscreen the Mutation leveraging on the same case not at basically, preliminary but started pushing right, Mutation Trial case of Capsule by data changes. methylation control also only study our release to again, study are screening, And have technology, CRC. Registrational -- on this or parallel our mutation into we sometime work CRC the we we expect a Penn, already leveraging so and we profile year Capsule, in advantages with can do

cancer we we are as preliminary liver cancer sometime to encouraging as mentioned the CRC do on a we will platform encouraging And data sometime -- as as also a MRD release multicenter well. this for MRD early MRD some I launching be So year. product our developing liver data expect study larger, well. we year. our this MRD And call, well see And study as early CRC your

Sung Ji Nam

much. so you Thank Great.

Sizhen Wang

Thank you, Sung Ji.

Operator

Credit open. line from The is Suisse

the line your is Yang from [ph] Huang You Credit now. you. Thank can Suisse ask open. question

your now. You can ask question

Unidentified Analyst

is Okay. My and nice quarter. from Yang the This congrats commercialization Credit question progress first first in Thank is you. the HCC quarter. Yes. for about Suisse,

probably HCCscreen? going design in? trial I we now second, details are you launch to What quarter? of a completed clinical provide we registrational more this we our the in you And the for trial later is maybe can on quarter the the sales? have also provide in our LDT detail sites and on So HCCscreen percentage trial a can have color first suppose number more sales

Sizhen Wang

the to Yeah, Yang. Sure, commercialization about HCCscreen. progress the update first on of question Yeah. your answer

we early previously In have to So It's cyclical but our I of we the HCCscreen in I HCC all strong as in of that can do I broken since is the last a QX channels here of not to remember, product has see to sales HTC from the QX. LDT these ability we quarterly that service, roughly sales at yet, our spring, revenue the XX% new of tell generate up, as process you about be the developing is first generate, And revenue with the new annual -- share that guided growth. mean, out can we quite QX. will this already our set quarter, is also XXXX. revenue that sustainable the has a reason started part exhibited screening have HCCscreen point, year, XX%

So, expect will revenue from this the of rest product the grow we for do year. this to continue

growing of So house, channels, months-by-months. last IKON much the work, year, year, that, centers, you we're the all is major have trend the we see started right, and this the with QX, hotels of for and [ph] their pretty rollout this the beginning check we same year, these actually in starting in of this down we're and do observe

a observed. trend that we this good very So, is

proper, education that proper channel. effective the this very As customer, outreach reflect with the we're or to

to We people lead awareness will the and then buying risk essentially -- going these strong. we generate population among are the the starting from high interest is

get, We and -- to announcement growth. revenue invest with the into best our at eventually sure the that market And was you area, Yang, and the upon -- high that also continue will need heavily the we sorry. profit believe reflect we this and belief screening, along pretty this to to this partners, I'm recent you want products what with to that, education. noticed work translate will also the invest to this, early need who people we So, to and stage, where our we, tell

revenue will house. a So, that's noticed the sustainable market like to you it channel. also we brand up have will okay, the punisher and that awareness. effectively so the will translate so, build the We believe eventually or essentially that to Yeah, JD another probably I the able was very Health And build recent our growth. educate announcement, good up said, be effectively again, be it

Unidentified Analyst

Yes, way, increase for the this guidance thanks, to to by consider for are year? you your HCCscreen going

Sizhen Wang

these growth. channel, really channels will as well all for Well, imagine, revenue partnerships right. future think, can potential, you have these a these then great us I position And

then We have said, But I penetration and these time, doubt will building partnership about market all the no again, right. education that. like take

the steps. away driving down coverage. drive R&D the do will next awareness structure We -- regulatory the last Service, into up call billion earning our have the and product, to its even serve big year And that obtain eventually to will down we're the on -- cancer. mean that, potential, hard will very drive on commercializing optimistic pushing and customer. growth and get focusing the going few believe And high drive the near hyper cost as in title assay and a expect a this just we're be we revenue working of -- our eventually expect potential population. get the and goal and not then turning is we see trial among we that the IVD LDT into investing we down take over this this working researching HCCscreen and only HCCscreen, product, a of purpose, when future, this have of are to tile build do we down you the We, you build timely see that potential eventually approval restated that from the full now like product And the we you eventually then we thus product. introduction team, partnership big, company, have expectation dollar heavily also we product that complete the regular but into also your in price we're that's reimbursement again in And rate down very to approval the the when target all death and ultimate when lease head -- I national will that -- we'll team which have will are liver period, application our industry cost approved can the is

Unidentified Analyst

details And the can HCCscreen? great. second maybe my on maybe the you Okay, traditional provide question, for more study

Sizhen Wang

will this mentioned our the last last call, product as is the Yes, call will we're said, HCCscreen. list the of very and much again, the stated, And the soon the Yun-Fu, And in And we patients it like in our thousands epi just be expect between completed design, be finalizing final we so and Nempa. registration finalized will pretty couple -- ago, sometime side. the and comparison months size running will do trial of our with I trial we're of a for a start year. of with the I head-to-head enrollment design [Indiscernible] clinical as several CMO next

that. So, we fully track on were for

Unidentified Analyst

baseline, and you're will last kind test be trials no or of time, is And okay, thinking? follow-up, as going to remember -- said we sharp do there a are I that various follow-up the only the

Yun-Fu Hu

cling This Yun-Fu, is truth, will test. just the additional at done not yes, just there be but -- the so, to of get time same tests our

are sensitivity study. ultrasound, As in ultrasound against hypothesis of test have our expect X,XXX our to Enercare specificity. is CT And Sizhen statistical end terms to the point than we MRI, comparison patients mentioned, the is truth no epi test but term by fewer AFP will for there will plus in our be the clinical non-inferior the the the and or superior

Unidentified Analyst

Okay.

to want So sure. make just

And a our done Test, time. off we Ultrasound get be after test we're people to have as AFP sample HCCscreen comparison a baseline. will or look Tools are if So will done Clinical Test at as And and a going Test. as baseline will some there the be

Yun-Fu Hu

Okay.

or term time. time, we approximately pages MRI and same the in and have study were our wrote or Ultrasound Test, all CT and HCCscreen by same at the clinical AFP So tools the

Unidentified Analyst

baseline. Okay, a as

Yun-Fu Hu

Yes.

will be no… there So

Unidentified Analyst

Okay. Oh, sorry.

Okay, okay.

Okay. sites, And how we okay? when things know many do are

Yun-Fu Hu

clinic the, sites? We are… mean You

Unidentified Analyst

sites, clinical The yes. Yeah.

Yun-Fu Hu

Yeah. both sites. eight five are around to We're sites probably looking some for

Unidentified Analyst

to is X,XXX. okay. Number about patients Five of eight,

Okay, got Thank you. it.

Operator

again. Instructions] Thanks you. [Operator once Thank

Sizhen Wang

Genetron (GTH) 24 May 212021 Q1 Earnings call transcript